Brief: Sino Biopharmaceutical Says Approval Granted For EGFR Inhibitor "TQB3002"
14/11/2024 12:51
Nov 14 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK :
* APPROVAL GRANTED FOR CLINICAL TRIALS OF EGFR INHIBITOR
"TQB3002"
IN US
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit